ArticleNPJ breast cancer2022

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.

Saranya Chumsri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.